Evidence map›Paper›PMID 27658536›Full record

Trial reportLeukemia & lymphoma2017

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.

Abhishek Maiti, Jorge E Cortes, Yolanda D Brown, Hagop M Kantarjian

Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Coordinated DNA 5-mC and RNA mExperimental & molecular medicine · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Abhishek Maitia Department of Internal Medicine , The University of Texas Health Science Center at Houston , Houston , TX , USA.
Jorge E Cortesb Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Yolanda D Brownb Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Hagop M Kantarjianb Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TOLERANCE INDUCTION BY MEGADOSE STEM CELL TRANSPLANTS IN CML--GVHD AND GVLP01CA049639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THALL, PETER F · 1990 to 2014
$41.8M
NCI NIH HHS P01 CA049639NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic AgentsAzacitidineBiomarkersBone MarrowFemaleFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNeoplasm, ResidualProtein Kinase InhibitorsTreatment OutcomeAntineoplastic AgentsAzacitidineBiomarkersFusion Proteins, bcr-ablProtein Kinase Inhibitors

Identifiers

PMID27658536
PMCPMC5250544
OpenAlexW2522820554

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.